Lauren Dembeck, PhD, is a freelance science & medical writer. She specializes in medicine and healthcare, with a focus on various medical specialties including hematology, immunology, oncology, and mental health care. Her work has been featured in publications such as Oncology Nurse Advisor, Infectious Disease Advisor, and The Cardiology Advisor, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lauren Dembeck's articles predominantly cite data related to medical research, hematology, cancer treatment, and blood disorders. She appears to focus on scientific themes within the healthcare and pharmaceutical sector. Given her reliance on data-backed information, she may be interested in receiving pitches from researchers or professionals with access to new and significant datasets or those who can provide expert analysis of existing ones.
Lauren appears to have a broad international scope rather than a specific geographic focus. Her coverage seems centered around developments in medical research and treatments globally without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lauren Dembeck
A shortened, outpatient blinatumomab regimen incorporating vial-sharing strategies and resulting in substantial cost savings appears to be safe and feasible in children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) in resource-limited settings, according to a retrospective study published in JCO Global Oncology.
By: Lauren Dembeck
Late acute and chronic graft vs host disease (GVHD) remain frequent complications and continue to drive long-term mortality following allogeneic hematopoietic cell transplantation (HCT), according to a 10-year follow-up study from the Chronic GVHD Consortium published in
By: Lauren Dembeck
Gasoyan H, Raza S, Rothberg MB, et al. Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies . ASCO 2026.
By: Lauren Dembeck
Golidocitinib maintenance therapy yields durable remissions and manageable toxicity among patients with peripheral T-cell lymphoma (PTCL) who respond to first-line therapy, according to a phase 2 multicenter study published in Blood Cancer Journal.
By: Lauren Dembeck
Patients with sickle cell disease (SCD) living in sub-Saharan Africa experience substantial disparities in disease management and access to care compared with patients in other low- and middle-income countries (LMICs) and high-income countries (HICs), according to findings published in Blood Global Hematology. 1
By: Lauren Dembeck
Intensive daunorubicin plus cytarabine therapy is associated with superior overall survival (OS) compared with single-agent clofarabine among fit older adults with newly diagnosed acute myeloid leukemia (AML), according to findings from the phase 3 E2906 trial published in Blood Neoplasia.
By: Lauren Dembeck
Older age and female sex are independently associated with reduced visual acuity among patients with treatment-naive diabetic macular edema (DME), in
By: Lauren Dembeck
Ravulizumab is a safe and effective treatment option for managing PNH during pregnancy that yields favorable maternal and neonatal outcomes.
By: Lauren Dembeck
A 10-year follow-up from the phase 3 RELEVANCE trial confirmed that first-line lenalidomide plus rituximab provides durable progression-free survival and overall survival (PFS and OS) comparable to rituximab-based immunochemotherapy (R-chemo) in patients with previously untreated advanced follicular lymphoma (FL), according to findings published in Blood.
By: Lauren Dembeck
Between 2012 and 2023, sickle cell disease (SCD) mortality increased in Colombia and was significantly higher in socioeconomically disadvantaged regions, according to findings from a nationwide population-based study published in Orphanet Journal of Rare Diseases.
